Cargando…

Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

OBJECTIVE: Intra-tumoral heterogeneity of (18)F‐fluorodeoxyglucose ((18)F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positive b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Guang, You, Shuhui, Xie, Yizhao, Gu, Bingxin, Liu, Cheng, Hu, Xichun, Song, Shaoli, wang, Biyun, Yang, Zhongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510219/
https://www.ncbi.nlm.nih.gov/pubmed/37726862
http://dx.doi.org/10.1186/s40644-023-00608-0
_version_ 1785107920208265216
author Ma, Guang
You, Shuhui
Xie, Yizhao
Gu, Bingxin
Liu, Cheng
Hu, Xichun
Song, Shaoli
wang, Biyun
Yang, Zhongyi
author_facet Ma, Guang
You, Shuhui
Xie, Yizhao
Gu, Bingxin
Liu, Cheng
Hu, Xichun
Song, Shaoli
wang, Biyun
Yang, Zhongyi
author_sort Ma, Guang
collection PubMed
description OBJECTIVE: Intra-tumoral heterogeneity of (18)F‐fluorodeoxyglucose ((18)F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positive breast cancer (MHBC) remains unknown. The aim of this study was to evaluate (18)F‐FDG uptake heterogeneity to predict the treatment outcome of the dual target therapy with Trastuzumab and Pertuzumab(TP) in MHBC. METHODS: Thirty-two patients with MHBC who underwent (18)F-FDG positron emission tomography/computed tomography (PET/CT) scan before TP were enrolled retrospectively. The region of interesting (ROI) of the lesions were drawn, and maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion glycolysis (TLG), metabolic tumor volume (MTV) and heterogeneity index (HI) were recorded. Correlation between PET/CT parameters and the treatment outcome was analyzed by Spearman Rank Test. The ability to predict prognosis were determined by time‐dependent survival receiver operating characteristic (ROC) analysis. And the survival analyses were then estimated by Kaplan‐Meier method and compared by log‐rank test. RESULTS: The survival analysis showed that HI(50%) calculated by delineating the lesion with 50%SUVmax as threshold was a significant predictor of patients with MHBC treated by the treatment with TP. Patients with HI(50%) (≥ 1.571) had a significantly worse prognosis of progression free survival (PFS) (6.87 vs. Not Reach, p = 0.001). The area under curve (AUC), the sensitivity and the specificity were 0.88, 100% and 63.6% for PFS, respectively. CONCLUSION: (18)F-FDG uptake heterogeneity may be useful for predicting the prognosis of MHBC patients treated by TP. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00608-0.
format Online
Article
Text
id pubmed-10510219
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105102192023-09-21 Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer Ma, Guang You, Shuhui Xie, Yizhao Gu, Bingxin Liu, Cheng Hu, Xichun Song, Shaoli wang, Biyun Yang, Zhongyi Cancer Imaging Research Article OBJECTIVE: Intra-tumoral heterogeneity of (18)F‐fluorodeoxyglucose ((18)F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positive breast cancer (MHBC) remains unknown. The aim of this study was to evaluate (18)F‐FDG uptake heterogeneity to predict the treatment outcome of the dual target therapy with Trastuzumab and Pertuzumab(TP) in MHBC. METHODS: Thirty-two patients with MHBC who underwent (18)F-FDG positron emission tomography/computed tomography (PET/CT) scan before TP were enrolled retrospectively. The region of interesting (ROI) of the lesions were drawn, and maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion glycolysis (TLG), metabolic tumor volume (MTV) and heterogeneity index (HI) were recorded. Correlation between PET/CT parameters and the treatment outcome was analyzed by Spearman Rank Test. The ability to predict prognosis were determined by time‐dependent survival receiver operating characteristic (ROC) analysis. And the survival analyses were then estimated by Kaplan‐Meier method and compared by log‐rank test. RESULTS: The survival analysis showed that HI(50%) calculated by delineating the lesion with 50%SUVmax as threshold was a significant predictor of patients with MHBC treated by the treatment with TP. Patients with HI(50%) (≥ 1.571) had a significantly worse prognosis of progression free survival (PFS) (6.87 vs. Not Reach, p = 0.001). The area under curve (AUC), the sensitivity and the specificity were 0.88, 100% and 63.6% for PFS, respectively. CONCLUSION: (18)F-FDG uptake heterogeneity may be useful for predicting the prognosis of MHBC patients treated by TP. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00608-0. BioMed Central 2023-09-19 /pmc/articles/PMC10510219/ /pubmed/37726862 http://dx.doi.org/10.1186/s40644-023-00608-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ma, Guang
You, Shuhui
Xie, Yizhao
Gu, Bingxin
Liu, Cheng
Hu, Xichun
Song, Shaoli
wang, Biyun
Yang, Zhongyi
Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
title Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
title_full Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
title_fullStr Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
title_full_unstemmed Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
title_short Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
title_sort pretreatment (18)f‐fdg uptake heterogeneity may predict treatment outcome of combined trastuzumab and pertuzumab therapy in patients with metastatic her2 positive breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510219/
https://www.ncbi.nlm.nih.gov/pubmed/37726862
http://dx.doi.org/10.1186/s40644-023-00608-0
work_keys_str_mv AT maguang pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer
AT youshuhui pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer
AT xieyizhao pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer
AT gubingxin pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer
AT liucheng pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer
AT huxichun pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer
AT songshaoli pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer
AT wangbiyun pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer
AT yangzhongyi pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer